An Occlusive Hydrocolloid-Based Patch Is Effective, Feasible, and Safe As a Treatment of Irritant Contact Dermatitis Due to Diabetes Devices in Children and Adolescents with Type 1 Diabetes

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

An Occlusive Hydrocolloid-Based Patch Is Effective, Feasible, and Safe As a Treatment of Irritant Contact Dermatitis Due to Diabetes Devices in Children and Adolescents with Type 1 Diabetes. / Berg, Anna Korsgaard; Sørensen, Mads Holmegaard; Knoth, Henrik Sigaard; Svensson, Jannet.

I: Diabetes Technology & Therapeutics, Bind 25, Nr. 10, 2023, s. 736-740.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Berg, AK, Sørensen, MH, Knoth, HS & Svensson, J 2023, 'An Occlusive Hydrocolloid-Based Patch Is Effective, Feasible, and Safe As a Treatment of Irritant Contact Dermatitis Due to Diabetes Devices in Children and Adolescents with Type 1 Diabetes', Diabetes Technology & Therapeutics, bind 25, nr. 10, s. 736-740. https://doi.org/10.1089/dia.2023.0224

APA

Berg, A. K., Sørensen, M. H., Knoth, H. S., & Svensson, J. (2023). An Occlusive Hydrocolloid-Based Patch Is Effective, Feasible, and Safe As a Treatment of Irritant Contact Dermatitis Due to Diabetes Devices in Children and Adolescents with Type 1 Diabetes. Diabetes Technology & Therapeutics, 25(10), 736-740. https://doi.org/10.1089/dia.2023.0224

Vancouver

Berg AK, Sørensen MH, Knoth HS, Svensson J. An Occlusive Hydrocolloid-Based Patch Is Effective, Feasible, and Safe As a Treatment of Irritant Contact Dermatitis Due to Diabetes Devices in Children and Adolescents with Type 1 Diabetes. Diabetes Technology & Therapeutics. 2023;25(10):736-740. https://doi.org/10.1089/dia.2023.0224

Author

Berg, Anna Korsgaard ; Sørensen, Mads Holmegaard ; Knoth, Henrik Sigaard ; Svensson, Jannet. / An Occlusive Hydrocolloid-Based Patch Is Effective, Feasible, and Safe As a Treatment of Irritant Contact Dermatitis Due to Diabetes Devices in Children and Adolescents with Type 1 Diabetes. I: Diabetes Technology & Therapeutics. 2023 ; Bind 25, Nr. 10. s. 736-740.

Bibtex

@article{26c84a3e1812424dae61054b4dcae4cc,
title = "An Occlusive Hydrocolloid-Based Patch Is Effective, Feasible, and Safe As a Treatment of Irritant Contact Dermatitis Due to Diabetes Devices in Children and Adolescents with Type 1 Diabetes",
abstract = "Irritant contact dermatitis (ICD) occurs frequently with the use of diabetes devices, but no guidelines for treatment exist. Since subsequent devices need intact skin for intended use, quick healing is crucial. Normal wound healing is expected to be 7-10 days. This was a single-center cross-over study that investigated the effectiveness of an occlusive hydrocolloid-based patch versus nonocclusive treatment of ICD. Participants were aged 6-20 years with active ICD caused by using diabetes device. First study period was patch treatment for 3 days. A control arm was initiated if a new ICD occurred within 30 days. ICD healed completely in 21% of the patch group but none in the controls. Itching was reported as an adverse event (AE) in both arms, but only one additional AE was noted in the patch arm: an infection at a different site from investigated. The hydrocolloid-based patch showed signs of faster healing of ICD with no additional AEs, but larger studies are needed.",
author = "Berg, {Anna Korsgaard} and S{\o}rensen, {Mads Holmegaard} and Knoth, {Henrik Sigaard} and Jannet Svensson",
year = "2023",
doi = "10.1089/dia.2023.0224",
language = "English",
volume = "25",
pages = "736--740",
journal = "Diabetes Technology & Therapeutics",
issn = "1520-9156",
publisher = "Mary AnnLiebert, Inc. Publishers",
number = "10",

}

RIS

TY - JOUR

T1 - An Occlusive Hydrocolloid-Based Patch Is Effective, Feasible, and Safe As a Treatment of Irritant Contact Dermatitis Due to Diabetes Devices in Children and Adolescents with Type 1 Diabetes

AU - Berg, Anna Korsgaard

AU - Sørensen, Mads Holmegaard

AU - Knoth, Henrik Sigaard

AU - Svensson, Jannet

PY - 2023

Y1 - 2023

N2 - Irritant contact dermatitis (ICD) occurs frequently with the use of diabetes devices, but no guidelines for treatment exist. Since subsequent devices need intact skin for intended use, quick healing is crucial. Normal wound healing is expected to be 7-10 days. This was a single-center cross-over study that investigated the effectiveness of an occlusive hydrocolloid-based patch versus nonocclusive treatment of ICD. Participants were aged 6-20 years with active ICD caused by using diabetes device. First study period was patch treatment for 3 days. A control arm was initiated if a new ICD occurred within 30 days. ICD healed completely in 21% of the patch group but none in the controls. Itching was reported as an adverse event (AE) in both arms, but only one additional AE was noted in the patch arm: an infection at a different site from investigated. The hydrocolloid-based patch showed signs of faster healing of ICD with no additional AEs, but larger studies are needed.

AB - Irritant contact dermatitis (ICD) occurs frequently with the use of diabetes devices, but no guidelines for treatment exist. Since subsequent devices need intact skin for intended use, quick healing is crucial. Normal wound healing is expected to be 7-10 days. This was a single-center cross-over study that investigated the effectiveness of an occlusive hydrocolloid-based patch versus nonocclusive treatment of ICD. Participants were aged 6-20 years with active ICD caused by using diabetes device. First study period was patch treatment for 3 days. A control arm was initiated if a new ICD occurred within 30 days. ICD healed completely in 21% of the patch group but none in the controls. Itching was reported as an adverse event (AE) in both arms, but only one additional AE was noted in the patch arm: an infection at a different site from investigated. The hydrocolloid-based patch showed signs of faster healing of ICD with no additional AEs, but larger studies are needed.

U2 - 10.1089/dia.2023.0224

DO - 10.1089/dia.2023.0224

M3 - Journal article

C2 - 37335752

VL - 25

SP - 736

EP - 740

JO - Diabetes Technology & Therapeutics

JF - Diabetes Technology & Therapeutics

SN - 1520-9156

IS - 10

ER -

ID: 370473573